ebe conference 05 dec 2017 - case study tisagenlecleucel · a case study from industry -...
TRANSCRIPT
![Page 1: EBE conference 05 Dec 2017 - Case study tisagenlecleucel · A case study from industry - tisagenlecleucel (CTL019) Miriam Fuchs, PhD Global Drug Development, Regulatory Affairs EBE](https://reader031.vdocument.in/reader031/viewer/2022030901/5b3f01e57f8b9a51528b8cab/html5/thumbnails/1.jpg)
1
![Page 2: EBE conference 05 Dec 2017 - Case study tisagenlecleucel · A case study from industry - tisagenlecleucel (CTL019) Miriam Fuchs, PhD Global Drug Development, Regulatory Affairs EBE](https://reader031.vdocument.in/reader031/viewer/2022030901/5b3f01e57f8b9a51528b8cab/html5/thumbnails/2.jpg)
2
![Page 3: EBE conference 05 Dec 2017 - Case study tisagenlecleucel · A case study from industry - tisagenlecleucel (CTL019) Miriam Fuchs, PhD Global Drug Development, Regulatory Affairs EBE](https://reader031.vdocument.in/reader031/viewer/2022030901/5b3f01e57f8b9a51528b8cab/html5/thumbnails/3.jpg)
3
![Page 4: EBE conference 05 Dec 2017 - Case study tisagenlecleucel · A case study from industry - tisagenlecleucel (CTL019) Miriam Fuchs, PhD Global Drug Development, Regulatory Affairs EBE](https://reader031.vdocument.in/reader031/viewer/2022030901/5b3f01e57f8b9a51528b8cab/html5/thumbnails/4.jpg)
4
![Page 5: EBE conference 05 Dec 2017 - Case study tisagenlecleucel · A case study from industry - tisagenlecleucel (CTL019) Miriam Fuchs, PhD Global Drug Development, Regulatory Affairs EBE](https://reader031.vdocument.in/reader031/viewer/2022030901/5b3f01e57f8b9a51528b8cab/html5/thumbnails/5.jpg)
5
![Page 6: EBE conference 05 Dec 2017 - Case study tisagenlecleucel · A case study from industry - tisagenlecleucel (CTL019) Miriam Fuchs, PhD Global Drug Development, Regulatory Affairs EBE](https://reader031.vdocument.in/reader031/viewer/2022030901/5b3f01e57f8b9a51528b8cab/html5/thumbnails/6.jpg)
6
![Page 7: EBE conference 05 Dec 2017 - Case study tisagenlecleucel · A case study from industry - tisagenlecleucel (CTL019) Miriam Fuchs, PhD Global Drug Development, Regulatory Affairs EBE](https://reader031.vdocument.in/reader031/viewer/2022030901/5b3f01e57f8b9a51528b8cab/html5/thumbnails/7.jpg)
7
![Page 8: EBE conference 05 Dec 2017 - Case study tisagenlecleucel · A case study from industry - tisagenlecleucel (CTL019) Miriam Fuchs, PhD Global Drug Development, Regulatory Affairs EBE](https://reader031.vdocument.in/reader031/viewer/2022030901/5b3f01e57f8b9a51528b8cab/html5/thumbnails/8.jpg)
8
![Page 9: EBE conference 05 Dec 2017 - Case study tisagenlecleucel · A case study from industry - tisagenlecleucel (CTL019) Miriam Fuchs, PhD Global Drug Development, Regulatory Affairs EBE](https://reader031.vdocument.in/reader031/viewer/2022030901/5b3f01e57f8b9a51528b8cab/html5/thumbnails/9.jpg)
CORE 11/30/2017 4:43 PMCORE 11/30/2017 4:43 PM11/30/2017 4:43 PMAbbott template 2 11/30/2017 4:43 PM
![Page 10: EBE conference 05 Dec 2017 - Case study tisagenlecleucel · A case study from industry - tisagenlecleucel (CTL019) Miriam Fuchs, PhD Global Drug Development, Regulatory Affairs EBE](https://reader031.vdocument.in/reader031/viewer/2022030901/5b3f01e57f8b9a51528b8cab/html5/thumbnails/10.jpg)
10
![Page 11: EBE conference 05 Dec 2017 - Case study tisagenlecleucel · A case study from industry - tisagenlecleucel (CTL019) Miriam Fuchs, PhD Global Drug Development, Regulatory Affairs EBE](https://reader031.vdocument.in/reader031/viewer/2022030901/5b3f01e57f8b9a51528b8cab/html5/thumbnails/11.jpg)
11
![Page 12: EBE conference 05 Dec 2017 - Case study tisagenlecleucel · A case study from industry - tisagenlecleucel (CTL019) Miriam Fuchs, PhD Global Drug Development, Regulatory Affairs EBE](https://reader031.vdocument.in/reader031/viewer/2022030901/5b3f01e57f8b9a51528b8cab/html5/thumbnails/12.jpg)
12
TRANSCRIPT
1
2
3
4
5
6
7
8
CORE 11/30/2017 4:43 PMCORE 11/30/2017 4:43 PM11/30/2017 4:43 PMAbbott template 2 11/30/2017 4:43 PM
10
11
12